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Materials and Methods:
We identified all men with NCCNÒ (National Comprehensive Cancer NetworkÒ) very low and low risk disease who underwent Oncotype DXÒ prostate testing at our institution from 2013 to 2016. Disease volume was characterized as the percent of positive cores, the number of cores with greater than 50% involvement, the largest involvement of any single core and prostate specific antigen density. Nonparametric testing was performed to compare the median Genomic Prostate ScoreÔ and the likelihood of favorable pathology findings between quartiles of disease volume. Results: We identified 112 (37.8%) and 184 men (62.2%) at NCCN very low and low risk, respectively. Median scores did not differ significantly between disease volume quartiles (all p >0.05). However, the median likelihood of favorable pathology findings statistically differed between volume quartiles (all <0.05). Seven of the 105 men (6.3%) with very low risk disease were reclassified at low risk and 13 of 181 (7.2%) with low risk disease were reclassified at intermediate risk. Genomic disease reclassification did not depend on biopsy tumor volume. Conclusions: In patients with NCCN very low and low risk prostate cancer genomic scores did not demonstrate meaningfully significant differences by volume based on clinically established cutoff points. Moreover, genomic scores identified and reclassified men with higher risk disease despite generally acceptable surveillance characteristics in this group according to grade and volume. This suggests that in patients at low risk the tumor biological potential measured by genomics rather than by volume should inform decisions on active surveillance candidacy.
Key Words: prostatic neoplasms; watchful waiting; genomics; risk factors; pathology, surgical DISEASE volume at prostate biopsy has been a key component of defining favorable risk prostate cancer as established by the landmark publication by Epstein et al. 1 Since that time, the definition of VLR prostate cancer has specified a low volume of disease at diagnosis based on 2 or fewer involved cores, maximum core involvement less than 50% and PSAD less than 0.15 ng/ml/gm. This definition, commonly known as the Epstein criteria, is used at many institutions to define candidates for active surveillance. 2 However, due to the inherent risk of sampling errors with needle biopsy the absence of these adverse features at biopsy does not guarantee favorable pathology findings at eventual radical prostatectomy. 1 Furthermore, despite long-term evidence of the safety of active surveillance in most men with pure GrdGrp 1 (ie Gleason score 3 þ 3) tumors 3, 4 violation of the Epstein criteria based on tumor volume has been used to exclude men against the recommendation for surveillance in some provider and institutional protocols. 5 The diagnostic inaccuracies of biopsy and traditional risk stratification measures create a need for improved methods to identify men at low risk for progression who may avoid initial therapy. This limitation is being addressed by the growing use of genomic biomarkers 6e8 and multiparametic magnetic resonance imaging as diagnostic tools. 9, 10 Oncotype DXÒ GPS is a 17-gene quantitative reverse transcriptase-polymerase chain reaction assay of select genes from 4 cancer related molecular pathways, including androgen signaling, cellular organization, stromal response and cellular proliferation. 11 It has been analytically 11 and clinically 12, 13 validated when measured on prostate biopsies to predict adverse pathology (GrdGrp 3 or higher or nonorgan confined disease) as well as time to biochemical recurrence and metastasis. 14 Further, GPS testing in a clinical setting demonstrated an increase in the recommendation for and adoption of active surveillance in patients with newly diagnosed prostate cancer. 15 This led to a recommendation in the current NCCNÒ guidelines to consider such tests when qualifying men for active surveillance. 16 In this study we determined prostate biopsy GPS scores and accompanying estimates of the likelihood of favorable pathology in men with Gleason grade group 1 (Gleason score 3 þ 3) tumors as a function of tumor volume. Our purpose was to determine whether some men who did not meet traditional Epstein criteria would be safe candidates for active surveillance based on the molecular rather than the histological features of the tumors.
MATERIALS AND METHODS
All men at our institution who underwent GPS testing performed on prostate biopsy samples to aid in clinical decision making were identified from a genomic database. Men were excluded from analysis if they had NCCN intermediate risk disease. 16 In 36 men, including 19 at LR and 17 at VLR, core biopsy samples were submitted for genomic testing but failed to provide enough quality RNA for analysis. A total of 296 men biopsied between 2013 and 2016 were included in analysis. Institutional review board approval was obtained for this study.
Clinical Data
We reviewed the electronic medical record and a prospectively maintained active surveillance database to obtain all relevant demographic and clinical data, including patient age at biopsy, ethnicity/race, body mass index, initial PSA, digital rectal examination findings and followup duration. We also collected biopsy data, including Gleason score, prostate volume on transrectal ultrasound, the total number of cores taken, the number of positive cores, the number of cores with greater than 50% involvement and the largest percent of core involvement. Men were stratified into NCCN VLR and LR disease based on baseline data according to NCCN guidelines. 16 Disease volume was defined as 1) the percent of positive cores, 2) the number of cores with greater than 50% involvement, 3) the largest involvement of any single core and 4) PSAD. Data on GPS and associated LFP, and the estimated probability of low grade (GrdGrp 1 or 2) and organ confined (pT2) disease were obtained from the Oncotype DX test result of each patient.
As mentioned, GPS is a 17-gene quantitative reverse transcriptase-polymerase chain reaction assay of select genes from 4 cancer related molecular pathways, including androgen signaling, cellular organization, stromal response and cellular proliferation. Testing is performed on tissue obtained from core prostate biopsies. LFP is the 0% to 99% probability reported in the initial iterations of the GPS test result. A calculation predicts the probability of adverse biological disease compared to that in men in a similar NCCN risk group.
Biopsy core number and location were determined according to physician preference and were not standardized. All biopsies were reviewed at our institution by expert genitourinary pathologists in accord with current ISUP (International Society of Urological Pathology) criteria. 17 
Statistical Methods
Descriptive statistics were performed to characterize the cohort. Data are presented as the median and IQR for continuous variables, and the frequency and proportion for categorical variables. The primary end point of this study was to compare the likelihood of favorable pathology (organ confined and with no primary Gleason pattern 4 or 5) between patients stratified by disease volume as estimated by the 3 mentioned volume parameters. Secondary end points included subanalysis to assess the rate of disease reclassification using GPS. Each volume parameter was divided into statistical quartiles with cutoff points at the 25th, 50th and 75th percentiles.
The Kruskal-Wallis test was used to compare median LFP among quartiles of each volume parameter. The Mann-Whitney U test was applied for tests between only 2 groups. All statistical tests were 2-sided with significance defined at p <0.05. Statistical analyses were performed using StataÒ, version 12.1 and IBMÒ SPSSÒ, version 24. Table 1 lists baseline cohort clinical and demographic data. In the cohort 112 (37.8%) and 184 men (62.2%) had NCCN VLR and LR prostate cancer, respectively. Median followup was 17.9 months (IQR 8.3e28.2). Median age was 62.5 years (IQR 58.0e66.6) and 13.5% of the patients selfidentified as African American. Median LFP was 86.0% (IQR 83.0e88.0) and 78.0% (IQR 73.0e81.0) in men at VLR and LR, respectively. At the last followup 214 patients (72.3%) remained on active surveillance, 44 (14.9%) had undergone radical prostatectomy, 31 (10.5%) had received brachytherapy and 6 (2.0%) had received external beam radiotherapy. Table 2 shows the relationship between the median GPS score, LFP and volume quartiles. GPS scores did not differ between quartile groups by any volume estimate or by PSAD ( fig. 1 ). There were statistically significant differences between the median LFP of each quartile group when stratified by the percent of positive cores, the number of cores with 50% or greater involvement, maximum core involvement and PSAD (all p <0.05, fig. 2 ).
RESULTS
In 98 men (33%) disease risk was reclassified after genomic testing ( 
DISCUSSION
Currently NCCN has adopted risk groups for prostate cancer based on relevant clinical and biopsy data adopted from studies by D'Amico, 18 
1 However, due to the inherent risk of sampling errors on needle biopsy the absence of these adverse histological features does not guarantee favorable prostate cancer pathology in men who undergo radical prostatectomy.
1 Initial validation studies of these criteria demonstrated 84% accuracy to predict a tumor that was insignificant, a term intended to define the lack of biological potential. 19 However, the accuracy of these criteria now varies from 37% to 76% 20, 21 following the 2005 ISUP changes to the Gleason grading system. 22 Nonetheless, these criteria have been a key driver of current active surveillance practices and use has demonstrated good clinical outcomes in men treated with active surveillance. 2, 5 In an effort to improve the accuracy of risk stratification several new schemes have been proposed to augment or replace NCCN criteria, including preoperative nomograms such as the MSKCC (Memorial Sloan Kettering Cancer Center) nomograms and risk calculators such as CAPRA (Cancer of the Prostate Risk Assessment). 23, 24 While these tools more accurately characterize risk in individual patients, they are still limited by the lack of biological data beyond that included in grade, stage and PSA. Recent studies have shown that several commercially available gene expression assays, commonly referred to as genomic tests, can further improve individual risk classification when combined with traditional clinical critiera. 12, 14 As a result the most recent NCCN guidelines now endorse the consideration of genomic testing when determining eligibility for active surveillance. 16 Prior studies have shown that tumor volume does not predict a worse outcome in patients with only GrdGrp 1 disease. 25, 26 However, in community practice most urologists are hesitant to place men with multiple biopsy cores of GrdGrp 1 or those with more than 50% of an individual core on surveillance. 5 In this study we sought to determine whether this hesitance is rationally based by performing the Oncotype DX prostate test to measure the biological potential of GrdGrp 1 tumors as a function of tumor volume by GPS and the estimation of LFP. The test performed similarly in our cohort as in other reported series with a reclassification rate of 6.3% for NCCN VLR to LR, 7.2% of LR to intermediate risk and 43% LR to VLR in our study compared to published rates of 6% to 9%, 10% to 11% and 33% to 51%, respectively. 20, 21 Also as expected we found that higher tumor volume was associated with lower LFP. However, the absolute differences were small across all measures of tumor volume and these differences did not correlate with a clinically meaningful difference in predicting reclassification to a higher NCCN risk group. In addition, we found no relationship between GPS score and tumor volume. A recent study demonstrated that men at NCCN VLR and LR with GPS scores below 30 were at 0% 10-year risk of metastasis. 27 In our cohort 62 of the 297 men (20.8%) had findings above this threshold irrespective of tumor volume. Furthermore, Whalen et al reported that an estimated LFP greater than 76% was associated with favorable pathology at radical prostatectomy. 28 In this study the estimated LFP ranged from 76.1% to 82.4% and only men in the highest quartile of tumor volume as estimated by the percent of maximal core involvement approached this threshold. In summary our findings suggest that in men with GrdGrp 1 disease the high tumor volume which is often considered unsafe for active surveillance in current clinical practice is usually associated with a high likelihood of favorable pathology. This suggests that eligibility for active surveillance should be based on the biological potential of the tumor rather than on tumor volume on biopsy. Recent data have demonstrated that genomic testing has an impact in helping providers and patients make the decision to pursue active surveillance. 29, 30 Although current genomic testing is costly, it is difficult to quantify the economic benefit of providing patients with reassurance in regard to a cancer diagnosis based on individual tumor biology, decreasing the rate of prostate cancer overtreatment and of the value of personalized care in our current health system.
Several limitations of our study warrant discussion. 1) The retrospective nature of this study is inherently subject to selection bias. Specifically genomic testing is not routinely offered to all patients at our institution as a result of cost and provider preference. Consequently this patient population and these results may not be generalizable. However, as noted the Oncotype DX prostate test in this cohort performed similarly as in published reports from other institutions.
2) This study was not designed to answer many clinically relevant questions regarding the usefulness of genomic testing. For example, what is the long-term durability of a favorable genomic test in men being treated with active surveillance? Can genomic testing be used as a surrogate for a confirmatory biopsy in surveillance protocols? Is genomic testing cost-effective for patients, providers and/or payors?
3) In this study we used reclassification based on genomic testing as an outcome, which is not the standard for measuring oncologic outcomes in prostate cancer. However, studies have demonstrated that genomic tests strongly correlate with oncologic outcomes such as adverse biological features at prostatectomy, biochemical failure and the development of metastatic disease. 14, 27 With time studies of genomic testing must evaluate hard oncologic outcomes such as prostate specific mortality, metastasis and biochemical failure in patients who progress to treatment. Unfortunately this was not possible in this cohort, which had a median followup of 17.9 months and a relatively few men who progressed to radical prostatectomy from surveillance.
Nonetheless, this study provides some insight into the relationship between prostate cancer volume at biopsy and genomic testing in a large cohort of men with prostate cancer.
CONCLUSIONS
An increasing volume of prostate cancer was not associated with adverse genomic scores as measured by GPS. Although disease volume was associated with decreasing LFP, this relationship did not appear to be clinically significant with the likelihood of favorable pathology varying only 5% between the highest and the lowest volume quartiles. Moreover, disease reclassification by genomics demonstrated no correlation with disease volume in this cohort of men with GrdGp 1 prostate cancer. This suggests that in patients at NCCN VLR and LR the biological potential of disease measured by genomics rather than by volume at biopsy should inform decisions on active surveillance candidacy.
